RGD Reference Report - Beta-adrenergic stimulation and myocardial function in the failing heart. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Beta-adrenergic stimulation and myocardial function in the failing heart.

Authors: El-Armouche, A  Eschenhagen, T 
Citation: El-Armouche A and Eschenhagen T, Heart Fail Rev. 2009 Dec;14(4):225-41.
RGD ID: 4140391
Pubmed: PMID:19110970   (View Abstract at PubMed)
DOI: DOI:10.1007/s10741-008-9132-8   (Journal Full-text)

The sympathetic nervous system provides the most powerful stimulation of cardiac function, brought about via norepinephrine and epinephrine and their postsynaptic beta-adrenergic receptors. More than 30 years after the first use of practolol in patients with heart failure beta blockers are now the mainstay of the pharmacological treatment of chronic heart failure. Many aspects of their mechanism of action are well understood, but others remain unresolved. This review focuses on a number of questions that are key to further developments in the field. What accounts for and what is the role of beta-adrenergic desensitization, a hallmark of the failing heart? Is part of this adaptation predominantly beneficial and should therefore be reinforced, another part mainly maladaptive and therefore a target for antagonists? Which lessons can be drawn from studies in genetically engineered mice, which from (pharmaco) genetic studies? Finally, what are promising targets downstream of beta-adrenergic receptors that go beyond the current neurohumoral blockade?

Objects Annotated

Genes (Rattus norvegicus)
Adrb1  (adrenoceptor beta 1)
Adrb2  (adrenoceptor beta 2)
Gnas  (GNAS complex locus)
Grk2  (G protein-coupled receptor kinase 2)
Grk5  (G protein-coupled receptor kinase 5)

Genes (Mus musculus)
Adrb1  (adrenergic receptor, beta 1)
Adrb2  (adrenergic receptor, beta 2)
Gnas  (GNAS complex locus)
Grk2  (G protein-coupled receptor kinase 2)
Grk5  (G protein-coupled receptor kinase 5)

Genes (Homo sapiens)
ADRB1  (adrenoceptor beta 1)
ADRB2  (adrenoceptor beta 2)
GNAS  (GNAS complex locus)
GRK2  (G protein-coupled receptor kinase 2)
GRK5  (G protein-coupled receptor kinase 5)


Additional Information